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Neonatal infection: a major burden with minimal funding
Further progress in decreasing child mortality depends 
on reducing the 2·9 million neonatal deaths each year, 
around a quarter of which are directly due to infection.1 
However, systemic underfunding is limiting research 
and threatens further advances. The need is great: an 
estimated 6·9 million neonates required treatment 
for possible serious bacterial infection in 2012 in high-
burden settings,2 and the Global Burden of Disease Study 
estimates suggest that neonatal infections account for 
around 3% of disability-adjusted life-years (DALYs), with 
insuﬃ  cient data to estimate long-term disability after 
sepsis or pneumonia.3,4 
Even with the limitations in the available data 
on DALYs, the funding gap is huge. The Research 
Investments in Global Health study5 analysed public 
and philanthropic infectious disease research awards 
to UK institutions (1997–2013), and compared them 
to the burden in DALYs,3 describing a new metric 
of “investment per DALY observed”. The results 
are stark: neonatal infectious diseases received the 
lowest investment of all infections, £0·01 per DALY. 
By contrast, HIV and malaria had investments of 
£0·46 and £0·34 per DALY (ﬁ gure, appendix) and 
some neglected tropical diseases have strikingly high 
investments—eg, African trypano somiasis received 
£9·06 per DALY.
Attracting additional funding and increasing capacity 
is essential to meet research needs and must be matched 
with improved scientiﬁ c reporting; the forthcoming 
Strengthening Publications Reporting Infections in 
Newborns Globally (SPRING) standards are an important 
step towards this goal. However, well funded research 
in neonatal infection is essential. In health facilities, 
high quality surveillance data can provide important 
information on cause6 and antimicrobial resistance.7 
But such data require signiﬁ cant resources, including 
strengthening laboratory quality control and assurance 
measures, and use and appropriate interpretation of 
molecular diagnostics to detect pathogens (including 
viruses). More population-based data are needed; 
these are diﬃ  cult to acquire because most neonatal 
deaths occur in the ﬁ rst few hours after birth when 
access to care may be limited. Results of the Aetiology 
of Neonatal Infections in South Asia (ANISA) study 
are awaited, and forthcoming work includes the Child 
Health and Mortality Prevention Surveillance Network 
funded by the Bill & Melinda Gates Foundation in south 
Asia and sub-Saharan Africa.
Preventing infection depends on improving our 
under standing of maternal health, including maternal 
colonisation, as well as vertical transmission (HIV, 
malaria, other congenital infections, and ascending 
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Figure: UK research investment per DALY per year for infections and number of child deaths in a year for those infections
The metric illustrates relative levels of investment for each infection and used the following equation (sum investment 1997–2009 / DALYs 20103) / 13 (number of 
years of investment included). The number of child deaths are given based on Global Burden of Disease estimates for 2013.11,10
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bacterial infections) and hospital-acquired infections, 
particularly with multiresistant Gram-negative bacteria. 
Infection control management is important, and 
interventions, isolated or as part of care bundles, need 
detailed, prospective evaluation in outbreak situations, 
such as those proposed by the International Nosocomial 
Infection Control Consortium.
Improving case management partly depends on 
improving recognition of danger signs by carers 
and primary health centres. Clinical algorithms used 
for diagnosing possible serious bacterial infection 
could be improved through the use of bedside tests, 
such as pulse oximetry, as well as point of care 
tests. Clinical trials have recently examined whether 
outpatient care can be provided to neonates who 
are not critically ill and where referral for hospital 
treatment is not possible.8 These trials have informed 
new WHO guidelines.9 However, further research is 
needed to determine health-system requirements 
for implementation, and whether this approach 
reduces uptake of referral to hospital, which remains 
the standard of care. There are important bottlenecks 
in health systems to improving neonatal infection 
case management,10 and overcoming these, with 
appropriate metrics to track neonatal care coverage, 
are essential. Future trials need to focus on improving 
mortality outcomes in newborns with sepsis and 
deﬁ ning management strategies in settings of varying 
levels of antimicrobial resistance. The optimum 
choice of drug, dose, and duration in settings of 
high resistance to WHO ﬁ rst-line empirical therapy is 
completely unknown.
A joined-up approach from funders and research 
institutions is urgently needed to strengthen neonatal 
infection research. This could be through a formal 
prioritisation exercise leading to calls for speciﬁ c 
research funding to support research on neonatal 
infection. Developing research capacity worldwide is 
essential to drive forward measures to reduce deaths11 
and disability from neonatal infection, and to reduce 
gross inequities in health.
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